Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3, multi-center, open label, randomized study of oral ABL001 (asciminib) versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors

X
Trial Profile

A phase 3, multi-center, open label, randomized study of oral ABL001 (asciminib) versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Asciminib (Primary) ; Bosutinib
  • Indications Chronic myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms ASCEMBL
  • Sponsors Novartis; Novartis Pharmaceuticals; Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 12 Dec 2023 Results assessing Impact of Mutations in Blood Cancer Related Genes on Clinical Outcomes in Chronic Myeloid Leukemia in Chronic Phase presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 12 Dec 2023 Results (cutoff: March 22, 2023,n=233)data from pts who experienced failure on Bosutinib and switched to Asciminib ,presented at the 65th American Society of Hematology Annual Meeting and Exposition.
    • 12 Dec 2023 Results (n=97)of treatment patterns and real-world clinical outcomes in USA, presented at the 65th American Society of Hematology Annual Meeting and Exposition
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top